Using Midazolam with Bupivacaine for Pain Relief after C-Section
Midazolam as an Adjuvant to Bupivacaine in Quadratus Lumborum Block After Caesarean Section; Does it Offer Better Pain Control? a Randomized Double Blind Clinical Trial
This study is testing if adding midazolam to bupivacaine can help women feel less pain and recover better after having a C-section.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 24 Years to 40 Years |
| Sex | Female |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05261672 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of midazolam as an adjuvant to bupivacaine in providing postoperative pain relief through an ultrasound-guided quadratus lumborum block for women undergoing cesarean sections. The quadratus lumborum block is a regional anesthesia technique that targets the abdominal wall nerves to alleviate pain. By combining midazolam with bupivacaine, the study aims to enhance analgesic effects and improve recovery outcomes for patients. The trial will assess pain levels and overall satisfaction with pain management following the procedure.
Who should consider this trial
Good fit: Ideal candidates are healthy pregnant women aged 24 to 40 years with a singleton pregnancy at or beyond 37 weeks gestation.
Not a fit: Patients with coagulopathy, anatomical abnormalities in the block region, or a history of chronic pain may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve pain management and recovery for women after cesarean sections.
How similar studies have performed: Previous studies have shown positive outcomes with midazolam in regional anesthesia, suggesting potential success for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status I or II * age from 24 to 40 years old * weight from 50 to 80 kg, * normal singleton pregnancy with a gestation of at least 37 weeks Exclusion Criteria: * Coagulopathy * maternal anatomic abnormalities in the block region * localized infection * incapable of comprehending or using the verbal rating pain scoring system * Included medications allergy * history of chronic pain or regular opioid use.
Where this trial is running
Assiut
- Emad Zarief Kamel Said — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Emad Z Kamel, MD
- Email: emadzarief@aun.edu.eg
- Phone: +201007046058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.